ALLMedicine™ Gastric Tumors Center

Mar 10th, 2023 - Gastric cancer is among the leading causes of cancer-related death worldwide. Surgery or radiation monotherapy are applicable as treatment for localized tumors, however, the majority of patients are diagnosed in an advanced disease state requiring...

Mar 2nd, 2023 - The Japanese diagnostic criteria for autoimmune gastritis (AIG) were established by the "Study Group on the establishment of diagnostic criteria for type A gastritis," which is related to a workshop associated with the Japan Gastroenterological En...

Feb 22nd, 2023 - Gastroblastoma is a rare gastric tumor composed of epithelial and spindle cell components. The characteristic MALAT-GLI1 fusion gene has only been identified in 5 reported cases. We report the morphological characterization of gastroblastoma with ...

Feb 13th, 2023 - PRIMARY OBJECTIVES: I. To determine the safe dose of olaparib with ramucirumab, but not to exceed olaparib dose of 300 mg twice daily (tablet formulation). (Phase I) II. To determine the efficacy of olaparib plus ramucirumab as measured by the obj...

Feb 1st, 2023 - Background: Greater than 90% of gastric tumors are of epithelial origin and are classified as adenocarcinomas; the remainders include GIST, carcinoid and lymphoma Gastric adenocarcinoma is rare in the United States (incidence 7.4 per 100,000) Mort...

Mar 10th, 2023 - Gastric cancer is among the leading causes of cancer-related death worldwide. Surgery or radiation monotherapy are applicable as treatment for localized tumors, however, the majority of patients are diagnosed in an advanced disease state requiring...

Feb 13th, 2023 - PRIMARY OBJECTIVES: I. To determine the safe dose of olaparib with ramucirumab, but not to exceed olaparib dose of 300 mg twice daily (tablet formulation). (Phase I) II. To determine the efficacy of olaparib plus ramucirumab as measured by the obj...

Feb 1st, 2023 - Background: Greater than 90% of gastric tumors are of epithelial origin and are classified as adenocarcinomas; the remainders include GIST, carcinoid and lymphoma Gastric adenocarcinoma is rare in the United States (incidence 7.4 per 100,000) Mort...

Jul 8th, 2022 - Some subtypes of gastric and cardia tumors such as adenocarcinoma or gastric linitis with disseminated cells respond poorly to the pre-operative chemotherapy, and some of them do not respond to chemotherapy usually performed. Doing chemotherapy in...

Jun 9th, 2022 - 6 healthy volunteers with whole-body PET/CT scans at 0-1.0, 2.0, 3.0 and 4.0 hours after tracer injection (mean dose, 4.93 ± 0.10 mCi) will be performed. During the imaging period, 1 mL blood samples will be obtained specifically at 1, 3, 5, 10, 3...

Oct 26th, 2022 - Key clinical point: The female sex, distal gastric tumors, and diabetes are risk factors for delayed gastric emptying (DGE) in patients who have undergone gastrectomy for gastric cancer. Major finding: Multivariate analysis revealed female sex (ad.

Aug 22nd, 2022 - Neoadjuvant nivolumab (Opdivo) plus ipilimumab (Yervoy) followed by adjuvant nivolumab elicited positive pathologic complete response (pCR) rates in patients with locally advanced resectable mismatch repair–deficient (dMMR) and/or microsatellite i...

Dec 8th, 2021 - NEW YORK (Reuters Health) - How long patients with resected gastric adenocarcinoma survive is tied to their preoperative sensitivity to chemotherapy, researchers report. "Interestingly, in patients with sensitive tumors, there was a significant su...

Oct 6th, 2021 - Bob T. Li, MD, MPH Fam-trastuzumab deruxtecan-nxki (Enhertu; DS-8201), a HER2-directed antibody¬—drug conjugate (ADC), demonstrated significant clinical activity in multiple non-breast, non-gastric cancer solid tumor types, according to findings ...

Oct 6th, 2021 - Manish A. Shah, MD The GLOW and DESTINY-Gastric01 trials showcase 2 novel agents coming down the pipeline in the treatment paradigm for patients with gastric cancers, according to Manish A. Shah, MD. The ongoing phase 3 GLOW study is enrolling p...